GC Genome Corporation (KOSDAQ:340450)

Market Cap	224.68B
Revenue	26.95B
Net Income	-332.67M
Shares Out	23.65M
EPS	-17.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	759,464
Average Volume	5,789,845
Open	9,670.00
Previous Close	9,680.00
Day's Range	9,300.00 - 9,680.00
52-Week Range	9,150.00 - 15,180.00
Beta	n/a
RSI	n/a
Earnings Date	n/a

About GC Genome

GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The compan...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 340450